加科思－Ｂ (1167.HK)

2.290 +0.430 (+23.12%) 市場開市。 截至 10:35AM HKT。

加科思－Ｂ

Building F2
No. 88 Kechuang 6th Street Beijing Economic-Technological Development Area
Beijing
China
86 10 5631 5466
https://www.jacobiopharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 301

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Yinxiang Wang	Executive Chairman & CEO	3.18M	無	1965
Ms. Xiaojie Wang	Executive Director & President of Administration	2.42M	無	1965
Ms. Yunyan Hu	Executive VP & Executive Director	2.56M	無	1962
Ms. Tao Yang	Vice President of Human Resources	無	無	無
Dr. Andrea Wang-Gillam M.D., Ph.D.	Executive VP, Chief Medical Officer and Global Head of R&D	無	無	1971
Ms. Yanping Wang	Executive Vice President of Non-Clinical R&D	無	無	無
Dr. Haijun Wang	Senior Vice President of Information & Data Management	無	無	無
Dr. Wei Long	Head of Drug Discovery	無	無	無
Ms. Yuli Ding	Executive Vice President of Clinical Development	無	無	無
Ms. Qing Xue	Joint Company Secretary	無	無	1989

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. The company was founded in 2015 and is headquartered in Beijing, China.

公司管治

截至 無 止，加科思－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。